cll outcomes after cd19 car-t with ibrutinib
Published 4 years ago • 253 plays • Length 3:50Download video MP4
Download video MP3
Similar videos
-
0:47
durable responses after cd19 car-t plus ibrutinib in cll
-
5:22
long-term outcomes of anti-cd19 car-t in r/r cll
-
3:42
factors associated with treatment response to cd19 car t-cell therapy in b-all
-
3:02
euplagia-1: phase i trial of glpg5201, a cd19 car-t product, in r/r cll and richter's transformation
-
2:12
cd19-car-t therapy for cll with richter’s transformation
-
5:12
cd19 car-t cell treatment: unravelling the role of b cells in sle
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
2:24
convert dicom ct to stl files
-
1:25
where are we with car-t in cll?
-
2:49
cd19 car-t therapy drives the expansion of clonal hematopoiesis and associated cytopenias in lbcl
-
1:59
the importance of assessing response to cd19 car-t therapy in lbcl to confirm disease persistence
-
2:57
latest advances in car-t therapy for cll and richter’s transformation
-
3:39
car t-cells in cll: the current landscape
-
2:01
determining which cd19-directed car-t product is best for each patient with lbcl
-
4:07
horizon scan: cll and car-t
-
3:32
cll and covid-19: patient outcomes
-
1:09
car-t for cll
-
2:26
clinical data for cd19-directed car t-cell products in all
-
2:19
long-term management of cll for improved outcomes
-
2:03
an exciting time for car t-cell therapy: promising results for b-all, nhl and cll
-
2:32
challenges with implementing cars in cll and the promise of allogeneic products
-
4:41
hd-car-1: 3rd-generation cd19-directed car-ts for r/r cll